Skip to main content
Top

Investigational New Drugs

Issue 2/1997

Content (11 Articles)

Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice

Lisa Polin, Frederick Valeriote, Kathryn White, Chiab Panchapor, Susan Pugh, Juiwanna Knight, Patricia LoRusso, Maha Hussain, Elaine Liversidge, Nancy Peltier, Trimurtulu Golakoti, Gregory Patterson, Richard Moore, Thomas H. Corbett

Phase I trial of Uracil-Tegafur (UFT) plus oral leucovorin: 14-day schedule

Richard Pazdur, Yvonne Lassere, Enrique Diaz-Canton, Beth Bready, Dah H. Ho

Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer

Eric K. Rowinsky, William A. Flood, Susan E. Sartorius, Kathy M. Bowling, David S. Ettinger

Early clinical investigaiton of sulofenur with a daily schedule in advanced solid tumours

Anders Krarup-Hansen, Hans Pedersen, Elo Andersen, Helle Andersen, Heine H. Hansen

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder

Masoud Khorsand, Joan Lange, Lynn Feun, Neil J. Clendeninn, Mary Collier, George Wilding

An ECOG Phase II Study of Amonafide in Unresectable or Recurrent Carcinoma of the Head and Neck (PB390)

Andrea N. Leaf, Donna Neuberg, Edward L. Schwartz, Scott Wadler, Paul S. Ritch, Janice P. Dutcher, George L. Adams

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine